Icon Advisers Inc. Co. Sells 6,200 Shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

Icon Advisers Inc. Co. lowered its position in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 7.4% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 77,074 shares of the specialty pharmaceutical company’s stock after selling 6,200 shares during the period. Icon Advisers Inc. Co. owned about 0.15% of Supernus Pharmaceuticals worth $2,550,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Financial Gravity Wealth Inc. bought a new position in Supernus Pharmaceuticals during the 1st quarter worth about $44,000. Bremer Bank National Association bought a new position in Supernus Pharmaceuticals during the 1st quarter worth about $94,000. Adams Diversified Equity Fund Inc. bought a new position in Supernus Pharmaceuticals during the 1st quarter worth about $200,000. Campbell & CO Investment Adviser LLC bought a new position in Supernus Pharmaceuticals during the 1st quarter worth about $204,000. Finally, Diversified Trust Co bought a new position in Supernus Pharmaceuticals during the 1st quarter worth about $208,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

A number of research firms have issued reports on SUPN. Zacks Investment Research cut Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday. Stifel Nicolaus set a $55.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Mizuho reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Wednesday, August 7th. Cowen set a $50.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Cantor Fitzgerald set a $60.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $54.43.



Shares of NASDAQ SUPN traded up $0.20 during mid-day trading on Friday, hitting $27.21. The company had a trading volume of 913 shares, compared to its average volume of 563,621. The company has a market capitalization of $1.43 billion, a PE ratio of 13.26, a price-to-earnings-growth ratio of 0.99 and a beta of 1.54. The firm has a 50-day simple moving average of $31.68 and a two-hundred day simple moving average of $34.69. The company has a current ratio of 2.72, a quick ratio of 2.53 and a debt-to-equity ratio of 0.70. Supernus Pharmaceuticals Inc has a one year low of $26.98 and a one year high of $51.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.05. The company had revenue of $104.70 million during the quarter, compared to analysts’ expectations of $109.67 million. Supernus Pharmaceuticals had a return on equity of 22.36% and a net margin of 25.66%. Supernus Pharmaceuticals’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.57 EPS. Sell-side analysts expect that Supernus Pharmaceuticals Inc will post 2.2 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Featured Story: When can a hold rating present a buying opportunity?

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.